Serological markers for melanoma (Q34010092)

30 July 2017

1 reference

title

Serological markers for melanoma (English)

1 reference

30 July 2017

Brochez L

1

1 reference

PubMed ID

10951131

30 July 2017

Naeyaert JM

series ordinal

2

1 reference

PubMed ID

10951131

30 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

British Journal of Dermatology

30 July 2017

1 reference

30 July 2017

143

1 reference

30 July 2017

2

1 reference

30 July 2017

256-268

1 reference

A review of the role of established tumour markers

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Elevated serum levels of S100 and survival in metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

A soluble protein characteristic of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Immunohistochemical localization of the Ca2+binding S100 proteins in normal human skin and melanocytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

The S-100 protein in cerebrospinal fluid: a simple ELISA method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Serum S100--a marker for disease monitoring in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Evaluation of new putative tumor markers for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

New prognostic factors in melanoma: mRNA tumour markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

The molecular detection of circulating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Utilization of polymerase chain reaction technology in the detection of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2000.03649.X

10.1046/J.1365-2133.2000.03649.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10951131